(95) reported that the combination of HSV-1 ICP0 null oncolytic virus KM100 and mitoxantrone, an immunogenic cell death-inducing chemotherapeutic drug, could significantly increase the survival benefit by increasing the infiltration of CD8+ T cells and neutrophils in the osteosarcoma microenvironment of BALB/c mice bearing HER-2/neu TUBO-derived tumors. The gene discussed is CD8A; the disease is osteosarcoma.